Thus, when the BCP-ALL patients with these karyotypes are treated by immunotherapy, methylation status and/or gene/cell-surface expression levels of the DR4 and DR5 genes might be useful biomarkers to predict therapeutic responses. This evidence concerns the gene TNFRSF10A and acute lymphoblastic leukemia.